Vimarsana
Biggest News Aggregation in the World

Page 9 - Libby Holman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Libby Holman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Libby Holman Today - Breaking & Trending Today

EISAI TO PRESENT THE LATEST ALZHEIMER'S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023 - Vimarsana News

EISAI TO PRESENT THE LATEST ALZHEIMER'S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023

/PRNewswire/ -- Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings on its...

KFF Health News: Why the next big hope for Alzheimer's might not help most Black patients | Community - Vimarsana News

KFF Health News: Why the next big hope for Alzheimer's might not help most Black patients | Community

The FDA on Thursday gave full approval to what many scientists and doctors believe is the first drug to show promise of slowing the progression of Alzheimer’s disease.

Why the next big hope for Alzheimer's, lecanemab, might not help most Black patients - Vimarsana News

Why the next big hope for Alzheimer's, lecanemab, might not help most Black patients

Lecanemab, the new Alzheimer's drug approved by the FDA, is believed by many scientists to be the first to show promise in slowing the progression of dementia. But critics say its rollout will increase racial disparities because Black people tend to be diagnosed too late for the drug to be effective. Plus, few Black people were included in clinical trials, leading to safety concerns.

FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease - Vimarsana News

FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...

FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease - Vimarsana News

FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease

07.07.2023 - The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease The Centers for Medicare & Medicaid Services (CMS) announced broader Medicare ...